Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism

Table 2 Non-BCMA-targeted CAR T cell clinical trials in multiple myeloma

Target antigen	Signaling domain	Clinical responses	Side effects	Conditioning	Registration code
CD19	4-1BB	ORR, 20% CR, 1 VGPR, 6 PR,2	Mild CRS Hypogammaglobulinemia Autologous GvHD	HDM + ASCT	NCT02135406
CD138	CD28	4 SD	Mild CRS	PCD, CP, or VAD	NCT01886976
	4-1BB	SD > 3 m, 4 Circulating PCL cells, 1	Infusion-related fever nausea and vomiting possible TLS	CP/Flu	?
	ND	PR,1	CRS grade 2	PCD, CP or VAD	?
Kappa LC	CD28	SD, 4	Mild CRS lymphopenia grade 3	CP or none	NCT00881920
NKG2DL	Dap10	ORR, 0%	Mild CRS	None	NCT02203825

BCMA B cell maturation antigen, CAR chimeric antigen receptor, ORR overall response rate, CR complete response, PR partial response, VGPR very good partial response, SD stable disease, CRS cytokine release syndrome, HDM high-dose melphalan, ASCT autologous stem cell transplantation, PCD pomalidomide-cyclophosphamide-dexamethasone, CP cyclophosphamide, VAD vincristine-doxorubicin-dexamethasone, Flu fludarabine, GvHD graft-vs.-host disease, TLS tumor lysis syndrome, ND no data, NKG2D natural killer group 2-member D

ISSN: 1757-6512